6-mercaptopurine transport in human lymphocytes: Correlation with drug-induced cytotoxicity

Journal of Digestive Diseases

Volumn 13, Issue 2, 2012, Pages 82-93

  Conklin, Laurie S ^a,b   Cuffari, Carmen ^a   Okazaki, Toshihiko ^a   Miao, Yinglei ^a   Saatian, Bahman ^a   Chen, Tian E ^a   Tse, Ming ^a   Brant, Steven R ^a   Li, Xuhang ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

6 mercaptopurine azathioprine; Crohn's disease; Drug resistance; Drug transport uptake; Inflammatory bowel disease

Indexed keywords

CARBON 14; CARRIER PROTEIN; CASPASE 3; CONCENTRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; RNA 18S; SODIUM; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; ASSAY; CYTOTOXICITY TEST; DRUG ACCUMULATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; DRUG UPTAKE; ENTERITIS; ENZYME ACTIVATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; APOPTOSIS; BINDING, COMPETITIVE; CARBON RADIOISOTOPES; CARRIER PROTEINS; CASPASE 3; CELL LINE, TRANSFORMED; CELL SURVIVAL; CYTOTOXINS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE (NADP+); HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTES; MALE; MIDDLE AGED; SODIUM; YOUNG ADULT;

EID: 84862922524     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00556.x     Document Type: Article

References (36)

1. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85: 717-22.
2. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
3. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-33.
4. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993; 88: 1198-205.
5. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 715-29.
6. Cuffari C, Seidman EG, Latour S, Théorêt Y. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can J Physiol Pharmacol 1996; 74: 580-5.
7. Kurowski V, Iven H. Plasma concentrations and organ distribution of thiopurines after oral application of azathioprine in mice. Cancer Chemother Pharmacol 1991; 28: 7-14.
8. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmocokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990; 30: 358-63.
9. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.
10. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 1986; 35: 3533-41.
11. + lymphocytes. J Clin Invest 2003; 111: 1133-45.
12. Hortelano S, Boscá L. 6-mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes. Mol Pharmacol 1997; 51: 414-21.
13. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA. Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 2006; 27: 416-25.
14. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 1286: 153-81.
15. Rose JB, Coe IR. Physiology of nucleoside transporters: back to the future... Physiology (Bethesda) 2008; 23: 41-8.
16. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735-43.
17. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447: 728-34.
18. Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004; 18: 385-93.
19. +/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics. J Biol Chem 2005; 280: 25436-49.
20. Penno MB, Pedrotti-Krueger M, Ray T. Cryopreservation of whole blood and isolated lymphocytes for B-cell transformation. J Tissue Cult Meth 1993; 15: 43-8.
21. Penno MB, Pedrotti-Krueger M, Ray T. Cryopreservation of human blood for B-cell immortalization. In: Doyle A, Griffiths JB, eds. Cell and Tissue Culture for Medical Research. New York, NY: John Wiley & Sons, 2000; 179-86.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
23. Wilson AP. Cytotoxicity and Viability Assays. In: Masters JRW, ed. Animal Cell Culture: A Practical Approach, 3rd edn. Oxford: Oxford University Press, 2000; 175-219.
24. Wijnholds J, Mol CA, van Deemter L etal. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 2000; 97: 7476-81.
25. Wielinga PR, Reid G, Challa EE etal. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 2002; 62: 1321-31.
26. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, Borst P. Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 2003; 278: 17664-71.
27. Scheper RJ, Broxterman HJ, Scheffer GL etal. Overexpression of a M(r) 110, 000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53: 1475-9.
28. Hu Y, Stephen AG, Cao J etal. A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells. Int J Cancer 2002; 97: 149-56.
29. Kitazono M, Okumura H, Ikeda R etal. Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer 2001; 91: 126-31.
30. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 2003; 22: 7458-67.
31. Herlevsen M, Oxford G, Owens CR, Conaway M, Theodorescu D. Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes. Mol Cancer Ther 2007; 6: 1804-13.
32. Nagai K, Nagasawa K, Kihara Y, Okuda H, Fujimoto S. Anticancer nucleobase analogues mercaptopurine and 6-thiouguanine are novel substrates for equilibrative nucleoside transporter 2. Int J Pharm 2007; 333: 56-61.
33. Fotoohi AK, Lindqvist M, Peterson C, Albertioni F. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem Biophys Res Commun 2006; 343: 208-15.
34. Zeng H, Lin ZP, Sartorelli AC. Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemic cell line L1210/VMDRC.06. Biochem Pharmacol 2004; 68: 911-21.
35. Dubinsky MC, Yang H, Hassard PV etal. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 904-15.
36. Roblin X, Peyrin-Biroulet L, Phelip JM, Nancey S, Flourie B. A 6-thioguanine nucleotide threshold level of 400 pmol/8×10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol 2008; 103: 3115-22.